Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Hemogenyx Pharmaceuticals Plc LSE:HEMO London Ordinary Share GB00BYX3WZ24 ORD GBP0.01
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 1.30 4,353,143 08:00:00
Bid Price Offer Price High Price Low Price Open Price
1.25 1.35 1.30 1.30 1.30
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology -3.78 -0.01 7
Last Trade Time Trade Type Trade Size Trade Price Currency
15:01:12 O 228,136 1.315 GBX

Hemogenyx Pharmaceuticals (HEMO) Latest News (1)

More Hemogenyx Pharmaceuticals News
Hemogenyx Pharmaceuticals Investors    Hemogenyx Pharmaceuticals Takeover Rumours

Hemogenyx Pharmaceuticals (HEMO) Discussions and Chat

Hemogenyx Pharmaceuticals Forums and Chat

Date Time Title Posts
27/6/202222:32HEMO8,127
22/3/202221:35Hemogenyx- Official Thread 356
14/3/202216:13HEMO 2020/21 Discussion MODERATED3,217
11/1/202212:16Hemogenyx - 2021 Entry to clinical status288
09/6/202115:22Hemogemyx - nomoderated25

Add a New Thread

Hemogenyx Pharmaceuticals (HEMO) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2022-06-27 14:01:131.32228,1362,999.99O
2022-06-27 13:37:151.3218,538243.77O
2022-06-27 11:47:421.322,59334.10O
2022-06-27 10:39:251.26250,0003,150.00O
2022-06-27 10:35:581.32250,0003,298.75O
View all Hemogenyx Pharmaceuticals trades in real-time

Hemogenyx Pharmaceuticals (HEMO) Top Chat Posts

DateSubject
27/6/2022
09:20
Hemogenyx Pharmaceuticals Daily Update: Hemogenyx Pharmaceuticals Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker HEMO. The last closing price for Hemogenyx Pharmaceuticals was 1.30p.
Hemogenyx Pharmaceuticals Plc has a 4 week average price of 1.23p and a 12 week average price of 1.23p.
The 1 year high share price is 3.13p while the 1 year low share price is currently 1.08p.
There are currently 546,415,988 shares in issue and the average daily traded volume is 3,906,474 shares. The market capitalisation of Hemogenyx Pharmaceuticals Plc is £7,103,407.84.
22/6/2022
10:17
jayrh: Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, has received notification from the Food and Drugs Administration ("FDA") that the proposed pre-Investigational New Drug ("pre-IND") meeting relating to the Company's lead product candidate Chimeric Antigen Receptor ("CAR") T-cells ("HEMO-CAR-T") is to be deferred until May 2022 as a result of a general FDA policy prioritizing work on COVID-19. The deferment of the meeting is not causing any delay in the development of the product candidate. In the meantime, the process will be dealt with by written responses by the FDA to a submission which is now being refined. A pre-IND meeting will then be necessary only if the written responses leave any matters unresolved. In light of this written process now implemented by FDA, there is no anticipated impact from the deferment on the IND filing for HEMO-CAR-T.What's going on?
16/3/2022
07:11
ashleyjv: Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, is pleased to announce that it has achieved proof of concept ("POC") for its Chimeric Bait Receptor ("CBR") platform technology. The Company has filed a seminal provisional patent application protecting its rights to the intellectual property ("IP") covering CBR. CBR is a novel platform technology that constitutes a new paradigm for treating viral infections. The essence of the CBR based approach is programming immune cells using a novel type of modifiable synthetic receptor to destroy viral pathogens. This approach can also potentially be used to program immune cells to destroy malignant cells causing certain types of cancer. Hemogenyx Pharmaceuticals initiated this project prior to the COVID-19 pandemic as a new approach to combat emerging or not yet known viral infections ("Disease X"). Data obtained during the initial period of development of the platform allowed the Company's scientists to expand the potential use of CBR into the area of cancer treatment. Detailed work has been undertaken by the scientists to prove the efficacy and widen the scope of the CBR platform and to file the provisional patent application. The Company's directors believe that the CBR platform is potentially very valuable and, so far as they are aware, no comparable developments are taking place. It is important to emphasise that, although work to date has been focussed on certain viruses, in particular SARS-COV-2 which causes COVID-19, as well as on particular types of cancer, the platform is, in principle, applicable to almost any form of virus. The Company's directors believe it is likely to be of value in particular to combat emerging or rare forms of viral infection, treating sufferers of such viruses where effective vaccines or anti-viral drugs have not yet been developed or in cases where they have failed to be effective. These may include the SARS-COV-2 virus as it mutates into future variants and certainly new forms of harmful viruses - which scientists have warned to be highly likely in the coming years. Major advantages of the CBR platform compared to other existing approaches of combatting viral infections are as follows: -- CBRs are insensitive to mutations of the targeted virus. For example, they work against known COVID-19 variants. In principle, any mutated form of the virus that remains capable of infecting cells will be attracted to the bait. -- CBRs are made from parts of naturally occurring proteins/receptors and endow immune cells with the ability to destroy invading pathogens. -- CBRs are modular synthetic receptors that can be reconfigured to attack almost any virus, bacteria or mammalian cells, including cancerous cells. The scientists of Hemogenyx Pharmaceuticals have now developed an initial set of CBRs. One is a CBR to program human immune cells to neutralize the SARS-COV-2 virus. The Company has successfully demonstrated in vitro that immune cells programmed with the CBR against SARS-COV-2 selectively consume a live synthetic virus. Importantly, the function of CBR was not affected by known mutations of the spike protein that endows the SARS-COV-2 virus with the ability to infect cells. In collaboration with an as yet undisclosed partner, the Company is planning in vivo tests to demonstrate that CBR could be used against infectious replicating SARS-COV-2 virus. Work also continues to expand the potential use of CBR into the area of cancer treatment. Having filed the patent application, Hemogenyx Pharmaceuticals is now able to move CBRs to the point of in vivo trials and will provide updates and more detailed scientific information to shareholders in due course. Meanwhile the Company's CAR-T and CDX projects continue to make good progress. Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented: "We are pleased to be able to give shareholders fuller details of the CBR platform on which we have been working for a significant period of time. We believe it is a ground-breaking new approach to treat emerging viral infections and to potentially become an effective new form of cancer treatment."
24/1/2022
17:01
justhereforhemo: Bager are you going to apologise for the part you played in trading/shorting the share price down? I dont think so, you won and like you said you made alot of money doing so, but yet your still desperate to also be seen as the hero. Lets say everyone had thought "Wow! Badger is right lets everyone sell and save our money!" How exactly would that have played out? How many people could have sold before the MMs just put a break on selling and gaped down the SP? I think you genuinely want people to believe your not a bad guy but you cannot see that the only way for people to have not lost money was for the share price to have been supported and boosted 12 months ago before the CLNs were ever drawn down. Go back a year when you and Purple were attacking Hemo with vigour, the mCap was what? 60mil? 12 mil draw down would have been 20%, there was something like 400mil shares. If you and others had gotten behind the company, supported Vlad, spread the word, then any conversions which were very slow and non damaging at the start would have been at 10+p and not 4/5/6p. Hemo would have gotten their money, investors would not have been diluted into the ground and we would not be having this discussion right now. The ONLY way for everyone to win was for the share price to go up, your forcing the share price down was never ever going to benefit anyone other than you and mint. Perhaps someone else would have stepped in and started tanking the SP, perhaps Mint would have been alot more aggressive at higher SP? We dont know and will never know, and its irrelevant, you won, you made alot of money and you cost lots of people including myself ALOT of money. But unlike you I am willing to move on because its the past and has zero impact on the fact that the CLNs are gone and hemo are within touching distance of clinical trials. HAve a good evening
24/1/2022
15:28
justhereforhemo: Badger, seriously do you think I have that sort of power? you were calling people all the names under the sun. I wont apologise for reporting posts but at the end of the day back then every other post was from someone saying "Reported, blocked". I dont work for LSE, I didnt ban you or anyone else, plenty of people have reported me and I got temporary bans for fighting with you on there, if you got a perm ban then your issue is with the LSE moderators, there is nothing I can do about it. As for Hemo as it stands today, they have plenty of cash, they are not doing any placings to lock in this low share price so whilst your right the share price is in the toilet right now I dont believe that will last when they start clinical trials (Provided they dont kill anyone).For a while you were very pro Hemo and by all accounts have done plenty of research into them over the years so you know the potential. I get you have made alot more by trading Hemo, but even you have to see the writing is on the wall and we are pretty close to re-rate time. They say bears are most vocal before they turn to bulls, I would not be surprised if you have managed to score a blinder of an entry today because of this Russia turmoil. If so, I look forward to the more bullish badger posting.
12/1/2022
07:21
the chairman elect: Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, is pleased to announce a further key step in the development of its CDX programme. Hemogenyx Pharmaceuticals and Selexis SA, a JSR Life Sciences company, have signed a service agreement to develop the cell line for the Company's CDX bispecific antibody for the treatment of acute myeloid leukemia (AML). Under the agreement, Hemogenyx Pharmaceuticals will leverage Selexis' proprietary SUREtechnology Platform™, a suite of cell line development tools and technologies that significantly reduces the time, effort, and costs associated with developing high-performance mammalian cell lines. The CDX bispecific is made using the Hemogenyx's proprietary humanised monoclonal antibody against a target on the surface of AML cells. CDX was co-developed by Hemogenyx Pharmaceuticals and Eli Lilly and Company ("Lilly"). This cutting-edge application of immune therapy offers a potentially more benign and effective form of treatment that, if successful, could have a significant impact on treatment and survival rates for AML. Following the completion of the co-development phase, Lilly granted the Company an exclusive worldwide licence to certain intellectual property developed by Lilly related to the CDX bispecific antibody for all uses, including the treatment of AML and other blood cancers. Dr. Vladislav Sandler, Chief Executive Officer and co-founder of Hemogenyx Pharmaceuticals commented, "We are delighted to partner with Selexis, and access its proprietary protein expression tools and technologies, IP and know-how. The partnership is key to advancing our CDX programme into clinical trials and accelerating the timeline to deliver this innovative therapy to patients in need of a more benign and effective treatment for AML." Mr Dirk Lange, CEO of Selexis, added, "There's an urgent need for effective treatments for AML, and we at Selexis are pleased to apply our technologies to help Hemogenyx advance the CDX bispecific antibody to the clinic. We've built a reputation for delivering cell lines rapidly and cost-effectively, without compromising safety. This is an exciting milestone for Hemogenyx Pharmaceuticals and we welcome the opportunity to join the company on its journey toward delivering a promising and effective therapy for patients with AML."
11/1/2022
10:23
justhereforhemo: And yet you still look... Which came first the chicken or the eggs? cause and effect. Fact is if you really have millions and decided a year ago you were going to be a Hemo bull instead of a bear and had bought and supported the share price instead of trashing it then any conversions would have been at a much higher share price and the dilution would have been much less. Predicting the snow is going to turn yellow just before whipping out your Johnson for a pee is hardly proof of being a genius :P I dont really understand why you are so defensive about this bit, you brag about how you were right and how you sold and shorted. You are not an idiot you know when you sell lots of share the share price drops, but yet you dont want any of the credit for the fact that the share price did drop and there was lots more dilution than necessary? I am over it, you won, you played a part in dropping the share price and causing more dilution than was necessary and you probably made a nice tidy profit doing so, how big was your influence? No idea but just man up and own your victory, frankly it was a smart play if you have enough cash to follow though and no moral qualms about attacking a cancer curing company. I DID do more DD on Mint AFTER the whole thing was finished and found out alot more about them and yes Vlad should never have gotten into bed with them, on that part you were spot on a year ago when you said dont trust them, I should have taken the time then to do the research so I apologise for dismissing your concerns about them. As for others who visit? I am sure your right some people will chance across these boards, but what exactly are they going to see? Page after page of you talking about CLNs from a year ago, or chat about wife beating or bible scriptures? If you want to be negative atleast keep it relevant. Maybe you think the FDA will reject the IND application? Perhaps you fear that HEMO-CAR-T will cause a cytokine storm, perhaps you believe the lab that is needed for clinical trials wont be ready in time? I dont know, pick something that actually matters. Calling someone a wife beater is just.....
09/1/2022
19:31
checkricky: To stay up to date you can register with the link below for the H.C. Wainwright BIOCONNECT Virtual Conference Starts this Monday 10th January till the 13th January 2022 hxxps://my.ct.events/register.aspx?meid=22d2962c-a482-43a2-8aad-53f12bd1b3da&;rpid=41d6be82-5fdd-4e3a-b857-a774c4e1a118 As per last RNS: Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, is pleased to announce its participation in the H.C. Wainwright Bioconnect Conference, in which the Company will be featured as a presenting company. The conference will be held on a virtual platform from January 10-13, 2022. As part of the Company's presentation, Dr. Vladislav Sandler, CEO of Hemogenyx Pharmaceuticals, will provide an overview of the Company's business and product candidates to conference attendees. If you are an institutional investor and would like to listen to the Company's presentation, please click on the following link to register for the conference: hxxps://hcwevents.com/bioconnect/. The conference will feature corporate presentations and panels both live and on-demand. Dr. Sandler's presentation is accessible using a webcast link. Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented: "Our presentation at the H.C. Wainwright Bioconnect Investment Conference provides the Company with a great opportunity to inform the investment community about our achievements and increase the Company's visibility globally. It also allows us to further establish Hemogenyx Pharmaceuticals as a leader in the development of medicines for the treatment of blood and autoimmune diseases." About Hemogenyx Pharmaceuticals plc Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility. The Company is a pre-clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as a platform technology that it uses as an engine for novel product development. For more than 50 years, bone marrow transplantation has been used to save the lives of patients suffering from blood diseases. The risks of toxicity and death that are associated with bone marrow transplantation, however, have meant that the procedure is restricted to use only as a last resort. The Company's technology has the potential to enable many more patients suffering from devastating blood diseases such as leukemia and lymphoma, as well as severe autoimmune diseases such as multiple sclerosis, aplastic anemia and systemic lupus erythematosus (Lupus), to benefit from bone marrow transplantation. About H.C. Wainwright & Co. H.C. Wainwright is a full‐service investment bank dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. H.C. Wainwright & Co. also provides research and sales and trading services to institutional investors. According to Sagient Research Systems, H.C. Wainwright's team is ranked as the #1 Placement Agent in terms of aggregate CMPO (confidentially marketed public offering), RD (registered direct offering) and PIPE (private investment in public equity) executed cumulatively since 1998.
09/1/2022
10:23
checkricky: To stay up to date you can register with the link below for the H.C. Wainwright BIOCONNECT Virtual Conference Starts this Monday 10th January till the 13th January 2022 my.ct.events/register.aspx?meid=22d2962c-a482-43a2-8aad-53f12bd1b3da&rpid=41d6be82-5fdd-4e3a-b857-a774c4e1a118 As per last RNS: Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, is pleased to announce its participation in the H.C. Wainwright Bioconnect Conference, in which the Company will be featured as a presenting company. The conference will be held on a virtual platform from January 10-13, 2022. As part of the Company's presentation, Dr. Vladislav Sandler, CEO of Hemogenyx Pharmaceuticals, will provide an overview of the Company's business and product candidates to conference attendees. If you are an institutional investor and would like to listen to the Company's presentation, please click on the following link to register for the conference: hxxps://hcwevents.com/bioconnect/. The conference will feature corporate presentations and panels both live and on-demand. Dr. Sandler's presentation is accessible using a webcast link. Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented: "Our presentation at the H.C. Wainwright Bioconnect Investment Conference provides the Company with a great opportunity to inform the investment community about our achievements and increase the Company's visibility globally. It also allows us to further establish Hemogenyx Pharmaceuticals as a leader in the development of medicines for the treatment of blood and autoimmune diseases." About Hemogenyx Pharmaceuticals plc Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility. The Company is a pre-clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as a platform technology that it uses as an engine for novel product development. For more than 50 years, bone marrow transplantation has been used to save the lives of patients suffering from blood diseases. The risks of toxicity and death that are associated with bone marrow transplantation, however, have meant that the procedure is restricted to use only as a last resort. The Company's technology has the potential to enable many more patients suffering from devastating blood diseases such as leukemia and lymphoma, as well as severe autoimmune diseases such as multiple sclerosis, aplastic anemia and systemic lupus erythematosus (Lupus), to benefit from bone marrow transplantation. About H.C. Wainwright & Co. H.C. Wainwright is a full‐service investment bank dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. H.C. Wainwright & Co. also provides research and sales and trading services to institutional investors. According to Sagient Research Systems, H.C. Wainwright's team is ranked as the #1 Placement Agent in terms of aggregate CMPO (confidentially marketed public offering), RD (registered direct offering) and PIPE (private investment in public equity) executed cumulatively since 1998.
06/1/2022
12:41
checkricky: BLAGGER60 AKA SUZI8 HOW MANY MORE TIMES..LOL ...STOP POSITING THE SAME SAME OLD OLD PROSPECTUS AND CLN DOOM STUFF DAY IN DAY OUT YOUR CLOGGING UP THIS BB WITH RUBBISH. We've heard it all before clown We've heard it all before We've heard it all before you clown. YOUR LOOKING LIKE A BIG DESPRATE CLOWN REPEATING YOUR SELF NOW WITH NO CREDABILITY NOW AS THE CURVE HAS TOTALY CHANGED CLN IN OLD NEWS THE HORIZON HAS CHANGED MOVE ON WITH THE TIMES OLD MAN... KEEP AN EYE ON THE HEMO SHARE PRICE IN THE NEXT FEW DAYS AND YOUR GONA GET A SUPRISE RISE VERY SOON AS BIG BUYERS ARE BUYING INTO HEMO.. REMEMBER MY WORDS BLAGGER60
06/1/2022
11:21
catsan: Hi Badger, I decided to read the prospectus as you suggested as I had not read it before. I appreciate your concern and I do take alot of what you post seriously so I have read the Risk Section and my thoughts are PART A – RISK FACTORS SPECIFIC AND MATERIAL TO THE GROUP Lack of IND/Funding - Well the funding is sorted, this prospectus led to the CLN and from that the group have secured enough money for the first clinical trials. The IND application is what they are doing right now so not overly concerned about this. They may not be able to market after clinical trials, there may be delays, they may fail clinical trials - This is common to every single pharma I am aware of, they can all fail, thats why the company is only priced at 17 million and not 2 billion, its to allow for the risk of failure, its priced in. Covid-19 might affect - Yes, I think it has slowed down progress. RISK FACTORS RELATING TO THE GROUP’S FINANCIAL POSITION Well alot of those risk factors came true which is why the share price is 2p, but the prospectus was a year ago when the share price was 10p or more I think? So it was a risk to share holders back then but not now as the CLNs are gone and the company has money in the bank. RISK FACTORS RELATING TO THE GROUP’S INTELLECTUAL PROPERTY RIGHTS From what I can see over the last year the company has mitigated this risk by securing multiple patents to protect its IP, so again no concerns here. RISK FACTORS RELATING TO TAXATION Changes in tax law and practice may impact Shareholders and the Group - I skimmed the rest of this, its generic. I appreciate your concern but there is nothing in this prospectus which is unique or special to hemogenyx, a year ago it may have been relevant pre CLNs and perhaps should have made people more cautious about investing back then but I dont see why it would deter anyone now. If anything the impact of the CLNs has just presented more of an opportunity to investors like myself who are able to buy now at low prices. I am sorry you have lost so much on GDR and I wholeheartedly agree with you, how our government has treated British businesses throughout Covid has been a disgrace! Brexit was supposed to be about building British industry and not shipping even more manufacturing abroad.
Hemogenyx Pharmaceuticals share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
HEMO
Hemogenyx ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20220628 04:09:13